Today: 21 May 2026
BAT stock in focus: UBS sticks with Buy on British American Tobacco ahead of Feb results
11 January 2026
1 min read

BAT stock in focus: UBS sticks with Buy on British American Tobacco ahead of Feb results

London, Jan 11, 2026, 09:07 GMT — The market has closed

  • BAT shares ended Friday’s session in London up 1.25%.
  • UBS stuck with its Buy rating and held the price target at GBP52, pointing to growth in 2026.
  • BAT’s full-year results, due Feb. 12, stand as the next major catalyst.

UBS has maintained its Buy rating on British American Tobacco, projecting the company will return to steady growth by 2026 as U.S. nicotine pouches and newer products gain momentum. The firm also held its price target steady at GBP52.

The call arrives as markets kick off a new week, with defensives drawing fresh attention and investors grappling with the direction of earnings revisions. For BAT, the upcoming results are near enough to be significant, and the key question remains whether reduced-risk products can shoulder a bigger share of growth.

BAT shares ended Friday at 4,060 pence, gaining 50 pence, or 1.25%, after fluctuating between 3,982 pence and 4,060 pence during the session.

UBS analyst Faham Baig highlighted that BAT’s “New Categories” segment—covering vaping, heated products, and oral nicotine pouches—might see sales climb over 20% by 2026. He also pointed to easier year-on-year comparisons in the company’s mainstay combustibles business.

The broker forecasted that this mix could fuel 5% “organic” sales growth next year, excluding currency fluctuations and acquisitions, compared to a consensus estimate of 3.2%. UBS also predicted BAT would “beat and raise” its guidance through 2026.

BAT has relied on cash returns to steady performance and bankroll its move into newer products. In a Dec. 9 pre-close update, the company forecast around 2% revenue growth and roughly 2% growth in adjusted profit from operations for 2025. It also reaffirmed its mid-term target range starting in 2026 but noted that next year’s results would likely sit at the lower end of that band.

The update also highlighted ongoing U.S. growth in modern oral products and hinted at stricter enforcement against illicit vaping goods, a persistent headache for legal brands. BAT confirmed it plans to continue launching and expanding its glo Hilo heated product in key markets throughout 2026.

The road ahead isn’t straightforward. Regulation keeps shifting in key markets, while the U.S. vapour segment faces ongoing pressure from illegal supply. This undercuts pricing and market share gains, despite rising demand.

Traders will be eyeing if BAT can stay above the 4,000p mark in the upcoming session, along with any fresh broker commentary supporting the 2026 recovery story. The next key event is BAT’s full-year earnings report, set for Feb. 12.

Stock Market Today

  • Nvidia (NVDA) Reports Strong Q1 2026 with Revenue Surging 85% and Robust Guidance
    May 20, 2026, 6:31 PM EDT. Nvidia (NASDAQ:NVDA) delivered an 85.2% year-on-year revenue increase to $81.62 billion in Q1 CY2026, beating analyst expectations by 3.5%. Its adjusted earnings per share of $1.87 also surpassed forecasts by 5.4%. The company's non-GAAP EBITDA margin rose to 69.2%, supported by operating margins climbing to 65.6% from 49.1% a year ago. Nvidia provided Q2 revenue guidance of $91 billion, 5.7% above consensus, signaling accelerating demand amid growth in AI infrastructure. CEO Jensen Huang highlighted the rapid expansion of AI factories as a key growth driver. The firm's five-year compounded annual revenue growth rate sits at 67.4%, with recent acceleration reflecting strong market positioning in semiconductors, despite cyclical industry risks.

Latest articles

EnerSys Stock Just Reversed After Earnings—The Guidance Beat Traders Wanted

EnerSys Stock Just Reversed After Earnings—The Guidance Beat Traders Wanted

21 May 2026
New York, May 20, 2026, 18:04 EDT EnerSys shares were indicated higher after the industrial battery and power systems company posted a quarterly earnings beat and a firmer-than-expected first-quarter outlook, a turn that came after the stock ended the regular session lower. The shares closed down 1.3% at $214.56 on Wednesday, with 708,643 shares changing hands; Google Finance showed an after-hours quote at $227, up 5.8%. That is the trade now: a down day in regular hours, then a better tone once the numbers hit. The report landed after the New York Stock Exchange close and pushed attention to the
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
AEVEX Stock Jumps After Hours as Drone Maker Posts 307% Revenue Surge and New Air Force Deal

AEVEX Stock Jumps After Hours as Drone Maker Posts 307% Revenue Surge and New Air Force Deal

21 May 2026
AEVEX Corp. shares surged over 10% after hours Wednesday following a first-quarter profit of $21 million and new U.S. Air Force contracts worth $15.6 million. Revenue jumped to $216.7 million, beating estimates. The company, which went public in April, raised its full-year revenue outlook to $600–$620 million. The stock had closed regular trading at $26.27, down 0.23%.
Meritage Homes stock jumps 10% on Trump mortgage-bond order — what to watch next week
Previous Story

Meritage Homes stock jumps 10% on Trump mortgage-bond order — what to watch next week

BigBear.ai stock (BBAI) eyes Monday open after Kraft Group, Patriots tie-up; share vote looms
Next Story

BigBear.ai stock (BBAI) eyes Monday open after Kraft Group, Patriots tie-up; share vote looms

Go toTop